- $26.89bn
- $26.81bn
- $4.03bn
- 95
- 14
- 51
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 31.8 | ||
| PEG Ratio (f) | 1.39 | ||
| EPS Growth (f) | 29.64% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.79 | ||
| Price to Tang. Book | 13.6 | ||
| Price to Free Cashflow | 42.63 | ||
| Price to Sales | 6.67 | ||
| EV to EBITDA | 32.79 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.89% | ||
| Return on Equity | 27.63% | ||
| Operating Margin | 14.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,926.7 | 2,448.5 | 2,909.8 | 3,622.3 | 4,033 | 4,605.94 | 5,317.48 | 22.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +303.66 | -55.38 | +36.31 | +56.87 | +15.95 | +33.57 | +22.73 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Directors
- Kevin Sayer CHM (63)
- Jereme Sylvain CFO (41)
- Sadie Stern CHO (46)
- Jacob Leach EVP (43)
- Donald Abbey EVP (54)
- Andrew Balo EVP (73)
- Paul Flynn EVP (52)
- Patrick Murphy EVP (42)
- Chad Patterson EVP (39)
- Barry Regan EVP (48)
- Sumi Shrishrimal SVP (42)
- Shelly Selvaraj SVP (62)
- Steven Pacelli GMG (49)
- Mark Foletta LED (61)
- Steven Altman IND (59)
- Nicholas Augustinos IND (62)
- Richard Collins IND (64)
- Karen Dahut IND (57)
- Bridgette Heller IND (60)
- Barbara Kahn IND (68)
- Kyle Malady IND (54)
- Jay Skyler IND (74)
- Eric Topol IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 13th, 1999
- Public Since
- April 14th, 2005
- No. of Shareholders
- 25
- No. of Employees
- 10,300
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 392,107,501
- Address
- 6340 Sequence Dr, SAN DIEGO, 92121-4356
- Web
- https://www.dexcom.com/
- Phone
- +1 8582000200
- Contact
- Sean Christensen
- Auditors
- Ernst & Young LLP
Latest News for DXCM
Upcoming Events for DXCM
Q1 2025 Dexcom Inc Earnings Release
Q1 2025 Dexcom Inc Earnings Call
Dexcom Inc Annual Shareholders Meeting
DexCom Inc Annual Shareholders Meeting
Q2 2025 Dexcom Inc Earnings Release
Similar to DXCM
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 20:14 UTC, shares in DexCom are trading at $68.57. This share price information is delayed by 15 minutes.
Shares in DexCom last closed at $68.57 and the price had moved by -48.77% over the past 365 days. In terms of relative price strength the DexCom share price has underperformed the S&P500 Index by -51.83% over the past year.
The overall consensus recommendation for DexCom is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDexCom does not currently pay a dividend.
DexCom does not currently pay a dividend.
DexCom does not currently pay a dividend.
To buy shares in DexCom you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $68.57, shares in DexCom had a market capitalisation of $26.89bn.
Here are the trading details for DexCom:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DXCM
Based on an overall assessment of its quality, value and momentum DexCom is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in DexCom is $101.20. That is 47.59% above the last closing price of $68.57.
Analysts covering DexCom currently have a consensus Earnings Per Share (EPS) forecast of $2.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DexCom. Over the past six months, its share price has outperformed the S&P500 Index by +4.98%.
As of the last closing price of $68.57, shares in DexCom were trading -12.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DexCom PE ratio based on its reported earnings over the past 12 months is 31.8. The shares last closed at $68.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
DexCom's management team is headed by:
- Kevin Sayer - CHM
- Jereme Sylvain - CFO
- Sadie Stern - CHO
- Jacob Leach - EVP
- Donald Abbey - EVP
- Andrew Balo - EVP
- Paul Flynn - EVP
- Patrick Murphy - EVP
- Chad Patterson - EVP
- Barry Regan - EVP
- Sumi Shrishrimal - SVP
- Shelly Selvaraj - SVP
- Steven Pacelli - GMG
- Mark Foletta - LED
- Steven Altman - IND
- Nicholas Augustinos - IND
- Richard Collins - IND
- Karen Dahut - IND
- Bridgette Heller - IND
- Barbara Kahn - IND
- Kyle Malady - IND
- Jay Skyler - IND
- Eric Topol - IND